MedPath

Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer

Not Applicable
Withdrawn
Conditions
Unresectable Pancreatic Cancer
Interventions
Procedure: Bilateral Thoracoscopic Splanchnicectomy
Registration Number
NCT03117556
Lead Sponsor
University of Louisville
Brief Summary

This study aims to compare the efficacy of bilateral thoracoscopic splanchnicectomy (BTS) to conventional narcotic analgesia for control of abdominal pain in patients with pancreatic ductal adenocarcinoma not amenable to surgical resection.

Detailed Description

All patients with unresectable pancreatic cancer will be considered for participation in this study. Patients with locally advanced or metastatic cancer that meet inclusion criteria will be randomized into one of two arms, treatment with BTS and narcotic analgesia or treatment with narcotic analgesia alone. After randomization a baseline pain score will be assessed using the visual analog pain scale. Narcotic dosage and frequency will be evaluated at the time of enrollment. A pre-treatment quality of life score will be recorded using the SF-12® Patient Questionnaire. Patients will also be queried about the presence of nausea and reflux.

After all baseline assessments are complete patients will be taken to the OR to undergo their assigned procedure. BTS and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. BTS will be performed as described in the study procedure. Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only. An evaluation will be completed postoperatively in which the length of stay, post-op complications, and chest X-ray results will be recorded. Follow-up assessments will be conducted 24-48 hours post-procedure and at the time of discharge. Further follow-up assessments will be conducted 14 days, 30 days, and 90 days post-procedure during an office visit with the clinical research team or medical oncology.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. Must be 18 years of age
  2. Diagnosed with stage III/IV pancreatic cancer
  3. Willing and able to comply with the protocol requirements
  4. Able to comprehend and have signed the Informed Consent Form (ICF) to participate in the study
Exclusion Criteria
  1. Participating in another clinical trial for the treatment of cancer at the time of screening
  2. Pregnant or currently breast feeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BTS InterventionBilateral Thoracoscopic SplanchnicectomyBilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
Primary Outcome Measures
NameTimeMethod
Abdominal pain1 year

Pain will be measured using a visual analog pain score

Daily Narcotic Requirements1 year

Narcotic usage will be monitored at each follow-up visit

Secondary Outcome Measures
NameTimeMethod
Presence of Nausea1 year

Patients will be queried about the presence of nausea using a questionnaire

Quality of Life Assessment1 year

Quality of Life will be measured using the SF-12® Patient Questionnaire

Presence of Reflux1 Year

Patients will be queried about the presence of reflux using a questionnaire

Use of Anti-emetics1 year

anti-emetic dosage will be measures at each follow-up visit

Trial Locations

Locations (2)

University of Louisville

🇺🇸

Louisville, Kentucky, United States

Greenville Memorial Hospital

🇺🇸

Greenville, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath